Since our strategy is to block Pol-β activity by small molecular compounds and increase the efficacy of TMZ, it will also benefit patients who carry wild-type or mutant APC gene; the mutant APC gene is the precursors of adenomas and carcinomas in familial adenomatous polyosis (FAP) colon cancer. The gene discussed is POLB; the disease is carcinoma.